Literature DB >> 11506410

Levodopa induces dyskinesias in normal squirrel monkeys.

D M Togasaki1, L Tan, P Protell, D A Di Monte, M Quik, J W Langston.   

Abstract

This study assessed whether or not levodopa induces dyskinesias in normal (ie, unlesioned) squirrel monkeys. All six animals treated twice daily with levodopa (15 mg/kg with carbidopa by oral gavage) for two weeks developed choreoathetoid dyskinesias, whereas none of the vehicle-treated animals displayed any abnormal movements. These dyskinesias did not merely reflect a generalized motor activation as locomotion was actually suppressed. The present data demonstrate that preexisting nigrostriatal damage is not necessary for the development of levodopa-induced dyskinesias.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11506410     DOI: 10.1002/ana.1099

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  9 in total

1.  Dyskinesias do not develop after chronic intermittent levodopa therapy in clinically hemiparkinsonian rhesus monkeys.

Authors:  Christopher A Lieu; Milind Deogaonkar; Roy A E Bakay; Thyagarajan Subramanian
Journal:  Parkinsonism Relat Disord       Date:  2010-11-11       Impact factor: 4.891

Review 2.  Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.

Authors:  Mahmoud M Iravani; Peter Jenner
Journal:  J Neural Transm (Vienna)       Date:  2011-09-01       Impact factor: 3.575

Review 3.  Presynaptic effects of levodopa and their possible role in dyskinesia.

Authors:  Eugene V Mosharov; Anders Borgkvist; David Sulzer
Journal:  Mov Disord       Date:  2014-12-01       Impact factor: 10.338

Review 4.  Non-human primate models of PD to test novel therapies.

Authors:  Marc Morissette; Thérèse Di Paolo
Journal:  J Neural Transm (Vienna)       Date:  2017-04-08       Impact factor: 3.575

5.  Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part I.

Authors:  R Miller
Journal:  Curr Neuropharmacol       Date:  2009-12       Impact factor: 7.363

Review 6.  Role for the nicotinic cholinergic system in movement disorders; therapeutic implications.

Authors:  Maryka Quik; Danhui Zhang; Xiomara A Perez; Tanuja Bordia
Journal:  Pharmacol Ther       Date:  2014-05-14       Impact factor: 12.310

7.  Dopamine neuron stimulation induces context-dependent abnormal involuntary movements in healthy rats.

Authors:  Julia Hunter; Alexandra Bova; Andrew Stevens; Daniel K Leventhal
Journal:  iScience       Date:  2022-02-22

8.  The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa.

Authors:  Roberto Cilia; Albert Akpalu; Fred Stephen Sarfo; Momodou Cham; Marianna Amboni; Emanuele Cereda; Margherita Fabbri; Patrick Adjei; John Akassi; Alba Bonetti; Gianni Pezzoli
Journal:  Brain       Date:  2014-07-17       Impact factor: 13.501

Review 9.  Levodopa treatment and dendritic spine pathology.

Authors:  Haruo Nishijima; Tatsuya Ueno; Yukihisa Funamizu; Shinya Ueno; Masahiko Tomiyama
Journal:  Mov Disord       Date:  2017-09-07       Impact factor: 10.338

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.